Yuanjiong Qi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuanjiong Qi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Haiwen Zhou
Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China
2 shared publicationsShichao Zhang
Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China
2 shared publications- Shiyong Qi
Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, China
2 shared publications Bocun Yi
Department of Urology, Tianjin Institute of Urology, The second Hospital of Tianjin Medical University, Tianjin 300211, China
1 shared publicationChenglong Xu
Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, 300211, China
1 shared publication- E. Du
Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University
1 shared publication
Latest Publications
- Open Access
- 13 May 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
A pH-responsive ultrasmall Fe–kaempferol nanoplatform ameliorates acute kidney injury by enhancing efferocytosis and metabolic reprogramming
Acute kidney injury (AKI) remains a major clinical challenge and is largely driven by excessive oxidative stress, inflammatory responses, and tubular cell apoptosis. However, effective therapeutic strategies that simultaneously target these pathological processes are still lacking. We developed a pH-responsive ultrasmall Fe-kaempferol (Fe-Kae) nanoplatform with coordinated antioxidant and anti-inflammatory activities for AKI treatment. Owing to their ultrasmall size and pH-responsive properties, Fe-Kae nanoparticles preferentially accumulated in injured renal tissues and exhibited robust renoprotective effects in multiple murine AKI models, including ischemia-reperfusion injury, cisplatin-induced nephrotoxicity, and calcium oxalate-induced kidney injury. Integrated transcriptomic and metabolomic analyses of ischemia-reperfusion-injured kidneys revealed that Fe-Kae treatment markedly enhanced efferocytosis-associated pathways and induced coordinated metabolic reprogramming, characterized by optimized tricarboxylic acid cycle activity and enhanced glutathione metabolism. This study establishes a nanomedicine-based therapeutic strategy that couples efferocytosis enhancement with metabolic reprogramming to achieve effective renoprotection. Our findings highlight pH-responsive ultrasmall metal-polyphenol nanoplatforms as a promising paradigm for the treatment of AKI.
- 13 May 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessA pH-responsive ultrasmall Fe–kaempferol nanoplatform ameliorates acute kidney injury by enhancing efferocytosis and metabolic reprogramming
Acute kidney injury (AKI) remains a major clinical challenge and is largely driven by excessive oxidative stress, inflammatory responses, and tubular cell apoptosis. However, effective therapeutic strategies that simultaneously target these pathological processes are still lacking. We developed a pH-responsive ultrasmall Fe-kaempferol (Fe-Kae) nanoplatform with coordinated antioxidant and anti-inflammatory activities for AKI treatment. Owing to their ultrasmall size and pH-responsive properties, Fe-Kae nanoparticles preferentially accumulated in injured renal tissues and exhibited robust renoprotective effects in multiple murine AKI models, including ischemia-reperfusion injury, cisplatin-induced nephrotoxicity, and calcium oxalate-induced kidney injury. Integrated transcriptomic and metabolomic analyses of ischemia-reperfusion-injured kidneys revealed that Fe-Kae treatment markedly enhanced efferocytosis-associated pathways and induced coordinated metabolic reprogramming, characterized by optimized tricarboxylic acid cycle activity and enhanced glutathione metabolism. This study establishes a nanomedicine-based therapeutic strategy that couples efferocytosis enhancement with metabolic reprogramming to achieve effective renoprotection. Our findings highlight pH-responsive ultrasmall metal-polyphenol nanoplatforms as a promising paradigm for the treatment of AKI.
- Open Access
- 24 November 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 307, 119458
Ozone aging amplifies the tumor-promoting effects associated with low-dose graphene oxide exposure in bladder tumors via the integrin αV signaling pathway
- 24 November 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 307, 119458
Open AccessOzone aging amplifies the tumor-promoting effects associated with low-dose graphene oxide exposure in bladder tumors via the integrin αV signaling pathway
- 5 July 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-9
Efficacy and safety of tip-bendable suction ureteral access sheath-assisted flexible ureteroscopic lithotripsy compared with mini-percutaneous nephrolithotomy for the management of 1–3 cm simple lower calyceal calculi: a prospective randomized controlled trial
Objective To assess the efficacy and safety of flexible ureteroscopic lithotripsy (f-URL) assisted by the tip-bendable suction ureteral access sheath (SUAS) and mini-percutaneous nephrolithotomy (mPCNL) for the treatment of simple lower calyx renal calculi. Methods A prospective randomized controlled trial was conducted on 102 patients with simple lower calyx renal calculi (with a diameter of 1 ~ 3 cm) admitted to the Second Hospital of Tianjin Medical University from December 2023 to February 2025. The patients were randomly assigned to the SUAS f-URL group (n = 49) and the mPCNL group (n = 53). The primary endpoint of the study was the immediate stone-free rate (SFR), while the secondary endpoints included operative time, anesthesia time, visual analogue scale (VAS) pain score, estimated blood loss, complication rate, length of hospital stay, hospitalization cost, and the SFR at 30 days postoperatively. Results The two groups had comparable baseline characteristics. The SUAS f-URL group demonstrated a similar immediate SFR compared to the mPCNL group (67.35% vs. 66.04%, p = 0.889). Compared to the mPCNL group, the SUAS f-URL group had a shorter anesthesia time (78.08 ± 29.79 vs. 94.62 ± 34.22 min, p = 0.011), a shorter postoperative hospital stay (3.00 [1.50, 3.00] vs. 3.00 [2.00, 5.50] days, p = 0.003), and lower overall costs (3171.21 ± 373.34 vs. 5056.69 ± 358.97 USD, p < 0.001). There were no statistically significant differences between the two groups in terms of postoperative complications, estimated blood loss, pain scores, or SFR at 30 days postoperatively. Conclusion Compared to mPCNL, SUAS f-URL achieved a similar SFR while offering advantages such as less anesthesia time, shorter hospitalization, and lower hospitalization costs. Moreover, it did not increase the incidence of perioperative complications such as infection and blood loss. Therefore, SUAS f-URL would be a viable alternative supported by preliminary evidence for the management of 10–30 mm simple lower calyceal renal calculi.
- 5 July 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-9
Efficacy and safety of tip-bendable suction ureteral access sheath-assisted flexible ureteroscopic lithotripsy compared with mini-percutaneous nephrolithotomy for the management of 1–3 cm simple lower calyceal calculi: a prospective randomized controlled trial
Objective To assess the efficacy and safety of flexible ureteroscopic lithotripsy (f-URL) assisted by the tip-bendable suction ureteral access sheath (SUAS) and mini-percutaneous nephrolithotomy (mPCNL) for the treatment of simple lower calyx renal calculi. Methods A prospective randomized controlled trial was conducted on 102 patients with simple lower calyx renal calculi (with a diameter of 1 ~ 3 cm) admitted to the Second Hospital of Tianjin Medical University from December 2023 to February 2025. The patients were randomly assigned to the SUAS f-URL group (n = 49) and the mPCNL group (n = 53). The primary endpoint of the study was the immediate stone-free rate (SFR), while the secondary endpoints included operative time, anesthesia time, visual analogue scale (VAS) pain score, estimated blood loss, complication rate, length of hospital stay, hospitalization cost, and the SFR at 30 days postoperatively. Results The two groups had comparable baseline characteristics. The SUAS f-URL group demonstrated a similar immediate SFR compared to the mPCNL group (67.35% vs. 66.04%, p = 0.889). Compared to the mPCNL group, the SUAS f-URL group had a shorter anesthesia time (78.08 ± 29.79 vs. 94.62 ± 34.22 min, p = 0.011), a shorter postoperative hospital stay (3.00 [1.50, 3.00] vs. 3.00 [2.00, 5.50] days, p = 0.003), and lower overall costs (3171.21 ± 373.34 vs. 5056.69 ± 358.97 USD, p < 0.001). There were no statistically significant differences between the two groups in terms of postoperative complications, estimated blood loss, pain scores, or SFR at 30 days postoperatively. Conclusion Compared to mPCNL, SUAS f-URL achieved a similar SFR while offering advantages such as less anesthesia time, shorter hospitalization, and lower hospitalization costs. Moreover, it did not increase the incidence of perioperative complications such as infection and blood loss. Therefore, SUAS f-URL would be a viable alternative supported by preliminary evidence for the management of 10–30 mm simple lower calyceal renal calculi.
- Top Cited PapersOpen Access
- 17 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 4911-4931
Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study
Background: Cancer-associated fibroblasts (CAFs) are found in primary and advanced tumours. They are primarily involved in tumour progression through complex mechanisms with other types of cells in the tumour microenvironment. However, essential fibroblasts-related genes (FRG) in bladder cancer still need to be explored, and there is a shortage of an ideal predictive model or molecular subtype for the progression and immune therapeutic assessment for bladder cancer, especially muscular-invasive bladder cancer based on the FRG. Materials and methods: CAF-related genes of bladder cancer were identified by analysing single-cell RNA sequence datasets, and bulk transcriptome datasets and gene signatures were used to characterize them. Then, 10 types of machine learning algorithms were utilised to determine the hallmark FRG and construct the FRG index (FRGI) and subtypes. Further molecular subtypes combined with CD8+ T-cells were established to predict the prognosis and immune therapy response. Results: Fifty-four BLCA-related FRG were screened by large-scale scRNA-sequence datasets. The machine learning algorithm established a 3-genes FRGI. High FRGI represented a worse outcome. Then, FRGI combined clinical variables to construct a nomogram, which shows high predictive performance for the prognosis of bladder cancer. Furthermore, the BLCA datasets were separated into two subtypes – fibroblast hot and cold types. In five independent BLCA cohorts, the fibroblast hot type showed worse outcomes than the cold type. Multiple cancer-related hallmark pathways are distinctively enriched in these two types. In addition, high FRGI or fibroblast hot type shows a worse immune therapeutic response. Then, four subtypes called CD8-FRG subtypes were established under the combination of FRG signature and activity of CD8+ T-cells, which turned out to be effective in predicting the prognosis and immune therapeutic response of bladder cancer in multiple independent datasets. Pathway enrichment analysis, multiple gene signatures, and epigenetic alteration characterize the CD8-FRG subtypes and provide a potential combination strategy method against bladder cancer. Conclusions: In summary, the authors established a novel FRGI and CD8-FRG subtype by large-scale datasets and organised analyses, which could accurately predict clinical outcomes and immune therapeutic response of BLCA after surgery.
- 17 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 4911-4931
Top Cited PapersOpen AccessSingle-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study
Background: Cancer-associated fibroblasts (CAFs) are found in primary and advanced tumours. They are primarily involved in tumour progression through complex mechanisms with other types of cells in the tumour microenvironment. However, essential fibroblasts-related genes (FRG) in bladder cancer still need to be explored, and there is a shortage of an ideal predictive model or molecular subtype for the progression and immune therapeutic assessment for bladder cancer, especially muscular-invasive bladder cancer based on the FRG. Materials and methods: CAF-related genes of bladder cancer were identified by analysing single-cell RNA sequence datasets, and bulk transcriptome datasets and gene signatures were used to characterize them. Then, 10 types of machine learning algorithms were utilised to determine the hallmark FRG and construct the FRG index (FRGI) and subtypes. Further molecular subtypes combined with CD8+ T-cells were established to predict the prognosis and immune therapy response. Results: Fifty-four BLCA-related FRG were screened by large-scale scRNA-sequence datasets. The machine learning algorithm established a 3-genes FRGI. High FRGI represented a worse outcome. Then, FRGI combined clinical variables to construct a nomogram, which shows high predictive performance for the prognosis of bladder cancer. Furthermore, the BLCA datasets were separated into two subtypes – fibroblast hot and cold types. In five independent BLCA cohorts, the fibroblast hot type showed worse outcomes than the cold type. Multiple cancer-related hallmark pathways are distinctively enriched in these two types. In addition, high FRGI or fibroblast hot type shows a worse immune therapeutic response. Then, four subtypes called CD8-FRG subtypes were established under the combination of FRG signature and activity of CD8+ T-cells, which turned out to be effective in predicting the prognosis and immune therapeutic response of bladder cancer in multiple independent datasets. Pathway enrichment analysis, multiple gene signatures, and epigenetic alteration characterize the CD8-FRG subtypes and provide a potential combination strategy method against bladder cancer. Conclusions: In summary, the authors established a novel FRGI and CD8-FRG subtype by large-scale datasets and organised analyses, which could accurately predict clinical outcomes and immune therapeutic response of BLCA after surgery.